X
[{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Biomarker Data Showing EDP1815","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flagship-Backed Evelo Biosciences Joins Covid-19 Hunt With Proposal for Bacteria Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences announces EDP1815 to advance into phase 2\/3 TACTIC-E COVID-19 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences to Present Clinical Data from Phase 1\/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX\u2122, to Treat Systemic Inflammatory Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience's Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$79.2 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $25.5 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Closes $25.5 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Evelo Biosciences
Filters
Companies By Therapeutic Area
Details:
EDP2939 is an orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of inflammatory diseases. It is being developed for the treament of psoriasis.
Lead Product(s):
EDP2939
Therapeutic Area: Dermatology
Product Name: EDP2939
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 17, 2023
Details:
The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate psoriasis.
Lead Product(s):
EDP2939
Therapeutic Area: Dermatology
Product Name: EDP2939
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Flagship Pioneering
Deal Size: $25.5 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
July 12, 2023
Details:
Evelo intends to use the net proceeds to fund the readout of its Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle, in moderate psoriasis.
Lead Product(s):
EDP2939
Therapeutic Area: Dermatology
Product Name: EDP2939
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BMO Capital Markets
Deal Size: $25.5 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
July 10, 2023
Details:
EDP2939 is an orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of inflammatory diseases. It is being developed for the treament of psoriasis.
Lead Product(s):
EDP2939
Therapeutic Area: Dermatology
Product Name: EDP2939
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 27, 2023
Details:
EDP1815 is an investigational orally delivered monoclonal microbial being developed for the treatment of inflammatory diseases. EDP1815 is a strain of Prevotella histicola, selected for its specific pharmacology.
Lead Product(s):
EDP1815
Therapeutic Area: Dermatology
Product Name: EDP1815
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Horizon Technology Finance Corporation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
December 16, 2022
Details:
The combined clinical and biomarker data presented today confirmed that our groundbreaking SINTAX-based medicine EDP1815 can resolve systemic inflammation without systemic exposure and with safety and tolerability data comparable to placebo.
Lead Product(s):
EDP1815
Therapeutic Area: Dermatology
Product Name: EDP1815
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 07, 2022
Details:
Evelo intends to use the net proceeds from the offering to continue the development of EDP1815 in a Phase 2 trial in atopic dermatitis; prepare to advance EDP1815 in registration trials in psoriasis and, upon receipt of positive Phase 2 data, atopic dermatitis.
Lead Product(s):
EDP1815
Therapeutic Area: Dermatology
Product Name: EDP1815
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Flagship Pioneering
Deal Size: $79.2 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
May 25, 2022
Details:
EDP1815, is a non-live pharmaceutical preparation of a strain of Prevotella histicola was well tolerated with safety data comparable to placebo: no drug-related serious adverse events, and no meaningful difference in infections or gastrointestinal events observed.
Lead Product(s):
EDP1815
Therapeutic Area: Dermatology
Product Name: EDP1815
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 26, 2022
Details:
The tolerability and safety data for EDP1815 in the trial was comparable to placebo, with the additional finding of no flare or rebound following discontinuation of therapy (which are often seen with other therapies for psoriasis).
Lead Product(s):
EDP1815
Therapeutic Area: Dermatology
Product Name: EDP1815
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 28, 2022
Details:
Oral daily treatment with EDP1867 administered prophylactically or therapeutically reduced the severity of disease as demonstrated by a decreased mean maximum score and a decreased incidence of relapse compared to placebo.
Lead Product(s):
EDP1867
Therapeutic Area: Immunology
Product Name: EDP1867
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 13, 2021